Altfest L J 13F: New $1.3M Stake in REGN

Altfest L J reported a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) with 1,670 shares valued at approximately $1.27 million. This information comes from the fund's latest Form 13F filing with the SEC, disclosed on October 27, 2026.

REGN Regeneron Pharmaceuticals, Inc.

$816.10 ▲ +5.53% year to date

1M 3M YTD

Daily close · Oct 27, 2026

What Changed in Altfest L J's Regeneron Position

Altfest L J opened a new position in Regeneron Pharmaceuticals, acquiring 1,670 shares. This new holding represents a value of about $1.27 million, which is 0.54% of the fund's total reported value of approximately $234.2 million.

Other Institutional Activity in Regeneron

Several other funds have made moves in Regeneron Pharmaceuticals recently. Dodge & Cox Inc. added 412,838 shares, increasing its total to about 4.87 million shares valued at approximately $3.98 billion. Meanwhile, Loring Wolcott & Coolidge Fiduciary Advisors cut its position by 26,114 shares, leaving it with 39,761 shares worth about $30.1 million. Evergreen Capital Management also reduced its stake by 3,547 shares, now holding 14,214 shares valued at around $10.8 million.

Regeneron Pharmaceuticals, Inc. Stock Up 1.0%

As of October 28, 2026, Regeneron Pharmaceuticals traded around $816.10. This price is about equal to its closing price on the filing date and sits 3.1% above its 50-day moving average. However, it is about 5% below its 52-week high of $859.34. The stock has a market cap of approximately $84 billion and a P/E ratio of about 20.18.

Recent Earnings

Regeneron Pharmaceuticals reported trailing twelve-month revenue of approximately $15.53 billion, with a net margin of 27.9%. The company is set to announce its next earnings on October 30, 2026.

Dividend

Regeneron pays an annual dividend of $3.76 per share, yielding about 0.46%. The payout ratio stands at 9%.

Insider Buying and Selling at Regeneron Pharmaceuticals, Inc.

Several insiders have sold shares recently. Director Kathryn Ph.D. Guarini sold 400 shares on August 10 at an average price of $800, totaling $320,000. She also sold another 400 shares on September 2 at $850, valued at $340,000. Officer Marion E Mccourt sold 2,346 shares on September 3, valued at about $2 million. Additionally, Co-Chief Scientific Officer Andrew J Murphy sold 4,147 shares on October 14 at an average price of approximately $772.70, totaling about $3.2 million.

Analysts Set New Price Targets

Analysts have been active in adjusting their ratings for Regeneron. On October 7, 2026, Truist Securities maintained a Buy rating with a target of $780, while RBC Capital also maintained a Sector Perform rating with a target of $810. UBS upgraded its rating to Buy with a target of $978 on October 15, and Piper Sandler maintained an Overweight rating with a target of $865 on October 19. TD Cowen also maintained a Buy rating with a target of $980 on October 21.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers and develops medicines to treat various diseases. The company focuses on areas such as eye diseases, allergies, cancer, and rare diseases. Its innovative approach to biotechnology helps it create effective treatments for complex health issues.

Bottom Line

Altfest L J's new position in Regeneron Pharmaceuticals is worth watching, especially with the upcoming earnings report on October 30, 2026. Investors should keep an eye on further filings and any changes in analyst ratings as they assess the company's performance.